Host Modulatory Effects of β-glucan on Localized Aggressive Periodontitis (NCT02402296) | Clinical Trial Compass
CompletedPhase 4
Host Modulatory Effects of β-glucan on Localized Aggressive Periodontitis
30 participantsStarted 2013-01
Plain-language summary
combining the non-surgical therapy with a well-tolerated substance that can stimulate protective immune responses like B-glucan, might effectively mount resolution pathways contributing to resolving of the chronic lesion observed in aggressive forms of periodontal disease.
Who can participate
Age range20 Years – 27 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Except for periodontitis, patients were systemically healthy as evaluated by modified Cornell medical index.
* No more than two teeth other than first molars and incisors, with probing depth (PD) ≥ 5mm, bleeding on probing (BOP), and clinical attachment level (CAL) ≥ 5mm.
* Rapid rate of attachment loss and bone destruction.
* A radiographic examination revealing an evidence of moderate to severe vertical bone loss around permanent incisors and first molar teeth.
* Every patient should have at least 20 teeth excluding third (3rd) molars, and at least an extraction-indicated tooth for a dento-periodontal affection.
* Familial aggregation.
Exclusion Criteria:
* Previous subgingival scaling and root planing, allergy to β-glucan, smoking, former smoking, pregnancy, need of antibiotic coverage for routine dental therapy, antibiotic therapy in the previous 6 months and allergy to chlorhexidine.
What they're measuring
1
Assessment of Change in Clinical Attachment Level (CAL)